000127948 001__ 127948
000127948 005__ 20240228135038.0
000127948 0247_ $$2doi$$a10.1038/leu.2014.75
000127948 0247_ $$2pmid$$apmid:24535407
000127948 0247_ $$2ISSN$$a0887-6924
000127948 0247_ $$2ISSN$$a1476-5551
000127948 0247_ $$2altmetric$$aaltmetric:2253223
000127948 037__ $$aDKFZ-2017-03970
000127948 041__ $$aeng
000127948 082__ $$a610
000127948 1001_ $$0P:(DE-HGF)0$$aMerz, M.$$b0$$eFirst author
000127948 245__ $$aPredictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma.
000127948 260__ $$aBasingstoke$$bNature Publ. Group$$c2014
000127948 3367_ $$2DRIVER$$aarticle
000127948 3367_ $$2DataCite$$aOutput Types/Journal article
000127948 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1521813901_5360
000127948 3367_ $$2BibTeX$$aARTICLE
000127948 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000127948 3367_ $$00$$2EndNote$$aJournal Article
000127948 520__ $$aPrevious studies demonstrated the relevance of focal lesions (FL) in whole-body magnetic resonance imaging (wb-MRI) at the initial workup of patients with smoldering multiple myeloma (SMM). The aim of this study was to assess the effects of longitudinal wb-MRIs on progression into multiple myeloma (MM). Sixty-three patients with SMM were analyzed who received at least two wb-MRIs for follow-up before progression into MM. Radiological progressive disease (MRI-PD) was defined as detection of new FL or increase in diameter of existing FL and a novel or progressive diffuse infiltration. Radiological stable disease (MRI-SD) was defined by no change compared with the prior MRI. Patients were followed-up every 3-6 months, including a serological and clinical evaluation. One Hundred and eighty-two wb-MRIs were analyzed. MRI-PD occurred in 31 patients (49%), and 25 (40%) patients developed MM. MRI-PD was highly significantly associated with progression into MM, regardless of findings at the initial MRI. In multivariate analysis, MRI-PD remained a risk factor, independent of relevant baseline parameters like serum monoclonal protein or ⩾95% aberrant plasma cells in the bone marrow. Patients with MRI-SD had no higher risk of progression, even when FL were present at the initial MRI. Therefore, MRI is suitable for the follow-up of patients with SMM.
000127948 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000127948 588__ $$aDataset connected to CrossRef, PubMed,
000127948 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, T.$$b1$$udkfz
000127948 7001_ $$0P:(DE-HGF)0$$aWagner, B.$$b2
000127948 7001_ $$aSauer, S.$$b3
000127948 7001_ $$aShah, S.$$b4
000127948 7001_ $$0P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3$$aRaab, M. S.$$b5$$udkfz
000127948 7001_ $$aJauch, A.$$b6
000127948 7001_ $$aNeben, K.$$b7
000127948 7001_ $$aHose, D.$$b8
000127948 7001_ $$aEgerer, G.$$b9
000127948 7001_ $$aWeber, M. A.$$b10
000127948 7001_ $$0P:(DE-He78)3e76653311420a51a5faeb80363bd73e$$aDelorme, S.$$b11$$udkfz
000127948 7001_ $$aGoldschmidt, H.$$b12
000127948 7001_ $$0P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5$$aHillengass, Jens$$b13$$eLast author$$udkfz
000127948 773__ $$0PERI:(DE-600)2008023-2$$a10.1038/leu.2014.75$$gVol. 28, no. 9, p. 1902 - 1908$$n9$$p1902 - 1908$$tLeukemia$$v28$$x1476-5551$$y2014
000127948 909CO $$ooai:inrepo02.dkfz.de:127948$$pVDB
000127948 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000127948 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000127948 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000127948 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000127948 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3e76653311420a51a5faeb80363bd73e$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000127948 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000127948 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000127948 9141_ $$y2014
000127948 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000127948 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000127948 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLEUKEMIA : 2015
000127948 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000127948 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000127948 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000127948 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000127948 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000127948 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000127948 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000127948 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000127948 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000127948 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bLEUKEMIA : 2015
000127948 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lRadiologie$$x0
000127948 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000127948 9201_ $$0I:(DE-He78)E013-20160331$$kE013$$lHämatoonkologische Bildgebung$$x2
000127948 9201_ $$0I:(DE-He78)G330-20160331$$kG330$$lKKE Molekulare Hämatologie/Onkologie$$x3
000127948 980__ $$ajournal
000127948 980__ $$aVDB
000127948 980__ $$aI:(DE-He78)E010-20160331
000127948 980__ $$aI:(DE-He78)C060-20160331
000127948 980__ $$aI:(DE-He78)E013-20160331
000127948 980__ $$aI:(DE-He78)G330-20160331
000127948 980__ $$aUNRESTRICTED